# Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets

> **NCT01226056** · PHASE1,PHASE2 · SUSPENDED · sponsor: **Southern Europe New Drug Organization** · enrollment: 45 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** RAD001 in combination with sorafenib

## Key facts

- **NCT ID:** NCT01226056
- **Lead sponsor:** Southern Europe New Drug Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2009-03
- **Primary completion:** 2012-09
- **Final completion:** 2012-12
- **Target enrollment:** 45 (ESTIMATED)
- **Why stopped:** toxicity (protocol amendment under approval)
- **Last updated:** 2010-10-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01226056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01226056, "Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01226056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*